Heterogeneous Cancer Cell Line Data Fusion for Identifying Novel Response Determinants in Precision Medicine

摘要

The most commonly used anticancer treatments include DNA-targeted, genome specific drugs such as topoisomerase inhibitors. Unfortunately, many patients do not respond to these cytotoxic drugs since it is not yet possible to identify genomic parameters for response or non-response. Understanding genomic networks which determine treatment response is thus a cornerstone to effective use of DNA-targeted drugs. Large cancer cell line databases with extensive genomic and drug response information provide opportunities to examine these networks and recover genomic determinants for response to DNA-targeted drugs. We utilize a novel data fusion framework based on Laplacian eigenmap embeddings to identify potential response determinants to the topoisomerase inhibitor Topotecan.